Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: Dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial

Journal of Clinical Oncology

Volumn 28, Issue 25, 2010, Pages 3945-3950

  Okines, Alicia F C ^a   Ashley, Sue E ^a   Cunningham, David ^a   Oates, Jacqueline ^a   Turner, Andrea ^a   Webb, Janine ^a   Saffery, Claire ^a   Chua, Yu Jo ^a   Chau, Ian ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; EPIRUBICIN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ACNE; ADD ON THERAPY; ADULT; ADVANCED ESOPHAGOGASTRIC CANCER; AGED; ALOPECIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; ESOPHAGUS CANCER; EVALUATION; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPOKALEMIA; INFECTION; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; STOMACH CANCER; STOMATITIS; UNDIFFERENTIATED CARCINOMA; VOMITING; ADENOCARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ESOPHAGUS TUMOR; MAXIMUM TOLERATED DOSE; MIDDLE AGED; STOMACH TUMOR;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; EPIRUBICIN; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS;

EID: 77957552916     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.2847     Document Type: Article

References (37)

1. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 55:74-108, 2005
2. Murad AM, Santiago FF, Petroianu A, et al: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37-41, 1993 (Pubitemid 23182046)
3. Pyrhönen S, Kuitunen T, Nyandoto P, et al: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587-591, 1995
4. Wagner AD, Grothe W, Haerting J, et al: Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903-2909, 2006 (Pubitemid 46630593)
5. Cunningham D, Starling N, Rao S, et al: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46, 2008
6. Siena S CJ, Tabernero J, Burkes RL, et al: Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial. Presented at 2010 Gastrointestinal Cancers Symposium, Orlando, FL, January 22-24, 2010
7. Peeters M PTJ, Hotko YS, Cervantes-Ruiperez A, et al: Randomized phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Patient-reported outcomes (PRO). Presented at 2010 Gastrointestinal Cancers Symposium, Orlando, FL, January 22-24, 2010
8. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
9. Wang KL, Wu TT, Choi IS, et al: Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: Association with poor outcome. Cancer 109:658-667, 2007 (Pubitemid 46233226)
10. Langer R, Von Rahden BH, Nahrig J, et al: Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: A tissue microarray study. J Clin Pathol 59:631-634, 2006 (Pubitemid 43886048)
11. Kim MA, Lee HS, Lee HE, et al: EGFR in gastric carcinomas: Prognostic significance of protein overexpression and high gene copy number. Histopathology 52:738-746, 2008 (Pubitemid 351600058)
12. Galizia G, Lieto E, Orditura M, et al: Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 31:1458-1468, 2007 (Pubitemid 46945355)
13. Lieto E, Ferraraccio F, Orditura M, et al: Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 15:69-79, 2008
14. Hecht JR, Patnaik A, Berlin J, et al: Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 110:980-988, 2007 (Pubitemid 47312862)
15. Sartore-Bianchi A, Moroni M, Veronese S, et al: Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 25:3238-3245, 2007 (Pubitemid 47325607)
16. Chau I, Norman AR, Cunningham D, et al: The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma: individual patient data from 1775 patients in four randomised controlled trials. Ann Oncol 20:885-891, 2009
17. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
18. Pinto C, Di Fabio F, Siena S, et al: Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 18:510-517, 2007 (Pubitemid 46359631)
19. Pinto C, Di Fabio F, Barone C, et al: Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer 101:1261-1268, 2009
20. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 24:4991-4997, 2006 (Pubitemid 46631401)
21. Lordick F, Luber B, Lorenzen S, et al: Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: A phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer 102:500-505, 2010
22. Lordick F, Lorenzen S, Stollfuss J, et al: Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer 93:190-194, 2005 (Pubitemid 41135888)
23. Maughan TS AR, Smith C, Seymour M, et al: Oxaliplatin and fluoropyrimidine chemotherapy plus or minus cetuximab: The effect of infusional 5FU or capecitabine on the outcomes of the MRC COIN randomised controlled trial RCT in advanced colorectal cancer ACRC. Presented at 2010 Gastrointestinal Cancers Symposium, Orlando, FL, January 22-24, 2010
24. Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663-671, 2009
25. Hecht JR, Mitchell E, Chidiac T, et al: A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27:672-680, 2009
26. Borner M, Koeberle D, Von Moos R, et al: Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: A randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol 19:1288-1292, 2008 (Pubitemid 351911959)
27. Souglakos J, Kalykaki A, Vamvakas L, et al: Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol 18:305-310, 2007 (Pubitemid 46323098)
28. Adams RA, Meade AM, Madi A, et al: Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br J Cancer 100:251-258, 2009
29. Schønnemann KR, Jensen HA, Yilmaz M, et al: Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer. Br J Cancer 99:858-861, 2008
30. Di Lauro L, Giacinti L, Arena MG, et al: Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma. J Exp Clin Cancer Res 28:34, 2009
31. Hejna M, Raderer M, Zacherl J, et al: Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: Results of the Central European Cooperative Oncology Group Study ESGAS. 1.2.001. Anticancer Drugs 19:535-539, 2008 (Pubitemid 351559607)
32. Neri B, Pantaleo P, Giommoni E, et al: Oxaliplatin, 5-fluorouracil/ leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: A phase II study. Br J Cancer 96:1043-1046, 2007 (Pubitemid 46608306)
33. Van Cutsem E, Köhne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417, 2009
34. Arber N, Shapira I, Ratan J, et al: Activation of c-K-ras mutations in human gastrointestinal tumors. Gastroenterology 118:1045-1050, 2000 (Pubitemid 30346981)
35. Sommerer F, Vieth M, Markwarth A, et al: Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma. Oncogene 23:554-558, 2004 (Pubitemid 38175010)
36. Stella G RLF, Barone C, Falcone A, et al: KRAS and BRAF mutational status as response biomarkers to cetuximab combination therapy in advanced gastric cancer patients. J Clin Oncol 27, 2009 (suppl; abstr e15503)
37. Yashiro M, Nishioka N, Hirakawa K: K-ras mutation influences macroscopic features of gastric carcinoma. J Surg Res 124:74-78, 2005 (Pubitemid 40269804)